The share price of AstraZaneca advanced 3.5 percent on July 21, 2017 as the company is going to launch its anticancer drug Osimertinib in India on July 27, 2017.
Osimertinib is an oral anticancer drug for management of lung cancer. It is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an appropriate test, whose disease has progressed on or after EGFR TKI therapy.
Osimertinib has been approved in over 45 countries, including the United States, EU, Japan, China, and other Asian countries. The company has already received import and market permission using Form 45 (Marketing Authorization) from the Drug Controller General of India for the drug.